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The pmgnosis f patients developing ve~tric~~r tachycardia 
or ventricular fi~~j~~a~~~~ 248 h after acute myocardial 
i~f~~ct~~n is poor. with 
years of f~~l~w”~~ study r 
~~~t~~jty rate is even hi 
tively early after the ons 
rted an 83% mortalit 
7 year if sustained v 
within 8 weeks. Di 
patients at high risk of sudden cardiac death, ~~ci~~~n~ 
a~~ulat~~y Holter e~e~tr~car~i~gra~~~c 0333 ~0nitQ~~~~ 
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and programmed lectrical stimulation (8-14). However. the 
role of the clinical history and 12 lead ECG in determining 
prognosis is not we!! established. 
Therefore, the present Dutch multicenter study was ini- 
tiated in 1984. Its aims were !) to assess PrOgnOSiS in patients 
with symptomatic ventricular tachycardia or ventr!cu!ar 
fibrillation late after infarction, and 2) to identify those 
baseline characteristics that independently determine prog- 
nosis; both evaluations were limited to ~jtiti~m receiving 
standard antiarrhythmic treatment. The study was designed 
as a prospective nonrandomized follow-up investigation. 
Organization. The study was carried out under the aus- 
pices of the Interuniversity Cardiology Institute of The 
Netherlands. Thirteen cardiology departments participated 
(see Appendix). The first patient was enrolled on April I, 
1984 and the last on April I, 1987. Central registry and 
processing of the data were done at the Department of
Clinical and Experimental c rdiology of the Academic Med- 
ical Center in Amsterdam. A steering committee was respon- 
sible for the scientific conduct of the study. 
Patient selection. Patients with documented sustained 
ventricular tachycardia or fibrillation occurring ~48 h after 
the onset of myocardial nfarction were ligible for the study, 
provided that at least one of the following symptoms oc- 
curred uring the arrhythmia: palpitation, chest pain, dysp- 
nea, dizziness, yncope or cardiac arrest. The diagnosis of 
(previous) myocardia! infarction was based on the presence 
of at least two of the following criteria: I) pathologic Q
waves on the ECG meeting Minnesota Code Manual criteria 
(13; 2) elevation ofcardiac serum enzymes; and 1) abnormal 
wall motion as documented byechocardiography, scintigra- 
phy or angiography. Patients were not registered if the 
attending cardiologist attributed the ventricular tachyar- 
rhythmia to pump failure, ischemia or imbalance of serum 
electrolytes. In addition, participating cardiologists did not 
register patients if the arrhythmia was considered to be 
caused by proarrhythmic effects of an antiarrhythmic drug. 
Proarrhythmic effects of drugs were considered in cases in 
which ventricdar fibrillation or a ventricular tachycardia 
with a rate >250 beatslmin occurred within 30 days after 
the prescription f ‘kre drug (16). The records of a!! patients 
were retrospectively reviewed by the study coordinator 
(A. R. W.); patients whose ntry criteria had been unequiv- 
d from the registry. 
Patients were initially treated 
with an antiarrhythmic drug; if this failed, a second rug was 
prescribed; and if that failed, a third drug was given. The first 
two drugs were preferably class 1 antiarrhythmic drugs (17). 
such as procainamide, quinidine, disopyramide, flecainide 
and Propafenone. Amiodarone was the drug of choice in the 
third phase. Participating cardiologists were not restricted in
guiding drug therapy. In addition, some departments u
“parallel testing of drugs.” N macologic treat 
was undertaken i  patients who ntricular tachyc 
or ventricular fibrillation refractory to drug treatment. 
Patients were prospectively followed up from entry in the 
study until April I, 1988. All patients attended an outpatient 
clinic at regular intervals. At ent data on clinical history, 
physical examination and the i 
lected. iin addition, informatio 
infarction and its compli 
tained. Therefore in some 
available with regzu-d to the 
follow-up study, symptomatic 
reover, causes 
were ascertained for a!! pati 
definition of outcome e 
main outcome vent in this 
mic event (sudden death, fatal or ~o~fata! s 
sustained ventricular tachycardia orventricular 
was considered a secondary outcome vent. A!! deaths 
categorized bytwo experienced cardiolo 
was defined as witnessed death within I
(new) symptoms. unwitnessed but unexpected 
death occurring during sleep. Documented fatal 
ventricular tachycardia or ventricular fibrillation 
ered a separate category. Sudden death and 
mented recurrent ventricu!ar tacbyarrhytbmias 
ered arrhythmic deaths. 
ata analysis. The occurrence of death is presented as 
cumulative incidences derived from actuarial survival curves 
and as incidence rates, which are defined as the total number 
of deaths divided by the total number of patient-years of 
follow-up study. The incidence rate quantifies the occur- 
rence of new events in relation to time and allows an 
adequate (and simple) description ofdifferences in mortality 
rates between groups with different durations of follow-up 
stl;dy (19). 
In bhe uttivariale analysis, the effect of a baseline char- 
acteristic s quantified by the risk ratio, defined as the ratio of 
two incidence rates: 95% confidence intervals were caicu- 
lated to indicate the precision of the risk ratio estimate. Ifthe 
95% confidence interval is > I, the association ofthe respec- 
tive variable with the mortality risk is statistically significant 
at a 5% level (p C 0.05). 
Ii1 liie tnulfivarictte analysis, Cox survival analysis ( 
portiona! hazards mode!) is used (20). The goal of this 
aralysis is to predict survival from a set of independent (risk) 
factors within the baseline characteristics. 
Acttmrial survivd c44rws are estimated with the Kaplan- 
Meier method (21). 
Definitions of baseline characteristics. The following def- 
initions were used. Vmttfcula~ tachy,cardia: tachycardia 
treatment in one of 
or aVF) or lateral (V,, B or 
~n$ete~~~~~e~ iqfiwriot~: infa~~tio~ in the presence of 
left bundle branch block. 
Of473 palients registered. 
83 were excluded because of violations of the admission 
protocol, such as no do~umenta:ion of the ventricular tach- 
yarrhythmia or nonsustained ventricular tdcbycardia (n = 
41); retrospective registration (n = 26): arrhyth 
ischemia (n = l), pump failure (n = 8) or both (n = I); no 
evidence of infarction (ra - 2); asymptomatic tachycardid 
(n = 3); and tachycardia of supraventricular instead of 
gin (n = I). Ultimately. 390 tients were 
ta analysis. The mean follow- period (2 1 
as 1.9 + 1.2 years (range 1 10 4). No patient was lost 
e sUudy gra, le 8). The following 
characteristics are of note: B) 24% of the index arrhythmias 
ocsurreJ after multiple myocardial infarctions but the infarc- 
tion preceding the arrhythmia was typically located in the 
anterior wall; 2) the most severe clinical condition in the first 
(77%). IlOw;-ver, were 
received this treatment fo 
AP 
ose who died and at the end of the study 
alive), 56 patients had undergone e 
by electrical catheter a 
with additional aneurysmec 
percutaneous transluminal coronary angioplasty and three 
patients went heart tra~sp~a~tatio~ because of con- 
~~rn~ta~t refractory heart failure. The majority of pa- 
tients (7X<) were treated by drugs only. 
Be 3). The cumulative mortality rate 
B and 2 years was 22% and 34%, 
. The overall incidence rate was 18 deathslli0 
patient-years. .Iixty-eight of 161 patieilts whose a~rhytbm~a 
developed with , 6 weeks after the infarction 
the hospital phase of infarction. Fifty-six 
deaths were related to a recurrent arrhythmic event. Sudden 
death. recurrent ventricular tachyarrhythmia and pump fail- 
ure were the three most ccmmon causes of death, with 
cumulative incidence, s 2 years of 11%. 8% and 6%. 
idence rates were 6. 4 
ecurrent ventricular ar- 
ventricular arrhythmia. In addition, of 3 I patients who died 
of recurrent ventricular ta~byarrhytbmia. 13 (42%) died 
during the hospital phase of the infarction. 
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Table 1. Baseline Characteristics of de 390 Patients in Relation to the Risk of Death 
No. (s/c) Mortality per 100 Pt-Years RR 95% Cl 
Gender 
Female 
Male 
Age (yrl 
c50 
50-60 
60-70 
>70 
Referral status 
Referred 
Nonreferred 
Multiple previous MIS 
No 
Yes 
Location of MI 
Inferior/posterior 
Undetermined 
Anterior 
Type of Ml 
Non-Q wave 
Undetermined 
Q wave 
Clinical condition+ 
Unknown 
Killip class I or II 
Killip class III or IV 
PosUt~km$an angina 
No 
Yes 
Primary sustained VT/VF+ 
Unknown 
No 
Yes 
Second degree AV block* 
Unknown 
No 
Yes 
RBBBS 
Unknown 
No 
Yes 
LBBB$ 
Unknown 
No 
Yes 
Complete heart blocks 
Unknown 
No 
Yes 
Index arrhythmia 
Sust VT 
VF 
Maximal rate of index VT ln = 268) tbeatslmin) 
Unknown 
100-150 
150-200 
208-250 
250-300 
300-350 
Signs or symptoms during index arrhythmia 
Syncone 
Other. 
Palpitation 
Cardiac arrest 
First VT/VF after MI under arrhythmic drugs 
No 
Yes 
First,;sz;e of VT/VF after MI 
>I year 
77 (20) 
313 (801 
165 
I9 z 0.7-1.8 
6 weeks-l year 
<6 weeks 
23 (6) 
107 (271 
98 1251 
lb2 (42) 26 1.8 I .3-2.5% 
‘Significant risk ratio: twithin semiacute phase of the infarction: Sduring the acute phase of infarction: #reference group. AV = atrioventricular: Cl = 
confidence interval of risk ratio: LBBB = left bundle branch block; MI = myocardial infarction; Pt-Years = patient-years: RBBB = right bundle branch block: 
RR = risk ratio: Sust = sustained: VF = ventricular fibrillation; VT = ventricular tachycardia. 
44llll 
346 tXYl 
55 (14) 
I18 (301 
154 (39) 
63 (161 
201 (52) 
189 (48) 
298 (76) 
92 (24) 
I29 (33) 
I2 (3) 
249 (64) 
25 (61 
20 (5) 
34.5 (89) 
40 (IO) 
301 (771 
49 (131 
30 (8) 
313 (801 
47 (121 
34 (9) 
290 (741 
66 (171 
38 t 101 
312 (801 
42t111 
36 (91 
307 (79) 
47 (121 
36 (9) 
340 ta77) 
I5 (41 
36 (91 
335 (861 
I9 (51 
268 (691 
122 (311 
II (3) 
39 i IO) 
127 (331 
76 t I91 
14 (41 
1 (0) 
32 (81 
160 (41) 
42 (Ill 
156 (401 
213 - 
18 0.9 OS-I.5 
11 
22 I 
11 k - 
34 ?.I 1.4-3.0* 
195 - 
17 0.9 0.6-1.3 
175 
24 1.4 I .o-2. I 
;;)!4 - 
20 I.3 0.9-1.9 
I? 
l7lk - 
I9 1.3 0.7-2.3 
- 
45 2.6 1.7-4.0* 
;;>s -
I7 I.0 
); I - 
1 
I4 0.7 
I;}# - 
I7 I.0 
;; B - 
1 
22 1.2 
I8 I.0 
156 - 
25 1.6 
0.6-I .6 
0.5-I .2 
0%I.7 
U.R-2.0 
0.4-2.4 
I. l-3.9% 
I. l-2.3’ 
0.6-1.3 
1.4-2.7 
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abhie 2. Treatment at 1 and 2 Years of Follow-Up 
FOHOW-Up 
No. patients alive 
Treatment 
Antiarrhythmic surgery 
AKD 
ECA 
Other 
Drugs only 
AKD = automatic implantable card~overter/de~b~i~lato~: ECA = electri- 
cal catheter ablation. 
ictio 
Eieven factors were i 
total mortality (Tab1 
95% ~o~fi~e~~~ interval was >I br ody six hmrs. The 
potentially relevant to prognosis as 
Figure 1. Kaplan-Meier survival curve for all 390 patients with total 
mortality as the outcome. Vertical limes represent the standard error 
of the mean. The number of patients at risk is indicated above the 
~o~~~~~ta~ axis. 
100 -h 
90 ii 
80 
3 
E 
?i 70 
.z 
2 
II ‘--+--._ %-h* 
z 60 - --I- 
t 
g 50 
1 a 40- 
1 2 3 
Study time (years) 
No. (2 year 
incidence):” 
Total mortality 133 (3G 
Cardiac auses 109 K!8%) 
Arrhythmic death 
Sudden death 41 (ll%) 
Documented recurrenl VTIVF 31 (8%) 
Other cardiac causes 
Bump failure wilhout recurrent MI 23 (6%) 
Recurrent Ml 2 (1%) 
Pump f;Gre and recurrent VTNF 8 (!%‘o 
Other car&K ci)usz\ 4 (1~~ 
Noncsrdiac causes 13 (3%) 
Unknown II 
+Obtained from the Kaplan-Meier survival curve. Abbreviations as in 
Table I. 
wave ~~~arct~o~, cardiac arrest Hip class 
rst 6 weeks after infarction an ishory of 
revious i~~arct~oms (Table 4 
Irserlts flze ~~e~~~t~~ ~n~~~tiilit~ rcrlc for ewh 
c$ hi possible c~omhif~cr1i0on.s of risk fktors (that is, patient 
profiles) baled on the results of the two ~~~t~variate models. 
For example , a patient developing the arrhythmia >6 weeks 
after the infarction and without any risk factor, has a 5% 
redicted risk of death after I year. For a 60 ye 
se arrhythmia developed within 6 weeks aft 
and who has cardiac arrest and anterior 
factors. the predicted 
. Rgsulls of Cox Survival Analysis 
Variable 
Risk 
Ratio* 95% Cl p Value 
A: First VTNF <6 Week, After Infarction 
Age >70 year\+ 4.5 2.6-7.7 
Cardiac arrest? I.7 I .o-2.8 
Killip class Ill or IVt 3.5 1.5-4.4 
Anterior MI ?? _._ I .I!-3.9 
Multiple previou\ Mls I.6 0.9-2.7 
13: First VTIVF >6 Weeks After infarction 
O.ONl 
0.025 
0.003 I 
0.0158 
0. IO.57 
Q wave MB ?.I 0.x-5.9 0.0734 
Cardiac arrest+ I.7 1.1-2.9 0.0455 
Killip class 111 or IVB I.? N-3.4 0.1861 
Multiple previous Mls 1.4 0.8-D 0.2559 
*The risk ratio was obtained as the exponent of the regression coefficient 
of the Cox model: *during index arrhythmia; iduring the semiacute phase of 
infarction. Abbreviations as in Table I. 
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Table 5. Predicted 1 Year Mortality (%I on the Basis of the 
Presence or Absence of Determinants of Death 
Killip class 111 or IV* + + f + - - - - 
Cardiac arrest? + + - - + + - - 
Multiple MI + - + - t - + - 
First VTNF C6 weeks 
after MI 
Age 270 yrt 
Anterior MI IM) 99 99 94 94 83 81 66 
Nonanterior MI 96 88 86 72 72 56 54 39 
Age <70 yrt 
Anterior MI 80 64 62 46 46 33 31 21 
Nonanterior Ml 52 38 36 25 25 17 16 10 
First VTlVF >6 weeks 
after MI 
Q wave Ml 38 29 24 26 18 I9 I6 I? 
Non-Q wave MI I8 13 II I2 8 9 7 5 
*Within the semiacute phase of infarction: +during the index arrhythmia. 
According to the patient profile. a related column and row can be determined. 
The numbers in Ihe crossing of the columns and rows represent the predicted 
mortality rate (in percent) after I year. See text for further explanation and 
examples. t = determinant present: - = determinant absent; other abbrevi- 
ations as in Table I. 
at high risk of death; the observed rates were 12%, 28% and 
54%, respectively. The observed mortality rate for each 
category accurately corresponded with the predicted rates in 
the low and intermediate risk groups. The model slightly 
overestimated the mortality rate in the high risk group. 
Recurrence of arrhythmia events (Gg. 2). At least one 
recurrent arrhythmic event was documented in 192 patients 
(49%). These first recurrences were nonfatal in 164 (85%) of 
the 192 patients. The cumulative rate for all (both fatal and 
nonfatal) recurrent arrhythmic events after 6 months and 1 
and 2 years was 39%. 43% and 49%. respectively, corre- 
sponding with an overall incidence rate of 38 events/l00 
patient-years. These findings illustrate that recurrent ar- 
rhythmic events occur early after the first episode of the 
arrhythmia. The cumulative rate for arrhythmic deaths after 
I and 2 years was !I% and l8%, respectively, which 
corresponds to an incidence rate of IO events/l00 patient- 
years. All patients wlio eventually received a cardioverterl 
defibrillator had a (nonfatal) recurrent arrhythmic event after 
entry into the study but before implantation of the device. 
Table 6. Observed and Predicted I Year Mortality Rates in 
390 Patients 
Risk 
Low 
Intermediate 
High 
Total 
No. of No. of 
Patients Deaths 
243 28 
92 26 
55 30 
390 84 
Observed 
Mortality 
(W 
I! 
28 
54 
22 
Predicted 
Mortality 
I%) 
I3 
27 
64 
24 
Fatal recurrent arrhythmic events (N = 72) 
2 90 
B 
= P 60 
e 
2 E 70 
f 
$ 60 
i 60 
811 recurrent a~r~yt~rnic events 04 = 192) 
10 
0 
1 2 3 
Study time (years) 
Figure 2. Kaplan-Meier curves f&r 72 patients with fatal recurrent 
arrhythmic events (upper curve) anti all (fatal and nonfatal) arrhyth- 
mic events (n = 192) (lower curve) as the outcome. Vertical Ii
represent the standard error of the mean. The number of patients at 
risk of fatal events (upper row) and of all arrhythmic events (lower 
row) are indicated above the horizontal axis. 
Nonfatal recurrences after implantation of the device, even 
if possible to assess, could not be taken into account. 
~r~~i~t~o~ of recurrrence of asrRyl ic events. In contrast 
to total mortality, no strong predictors of recurrent arrhyth- 
mic events could be identified. All that can be said is that I9 
(21%) of 92 patients with multiple infarctions died suddenly 
compared with 22 (7%) of 298 patients with only one 
previous acute myocardial infarction. In addition, 2 (3%) of 
66 patients with primary sustained ventricular tachycardia or 
ventricular fibrillation in the acute phase of infarction died 
suddenly compared with 32 (11%) of 290 patients without 
primary sustained ventricular tachycardia or ventricular 
fibrillation. Also, 33 (67%) of 49 patients who were in Killip 
class I11 or IV during the firsr 6 weeks after infarction 
developed a new arrhythmic event compared with 140 (46%) 
of 301 patients who were in a better clinical condition. 
However, none of these univariate predictors was suffi- 
ciently strong to warrant multivariate analysis. 
The natural history of sustained ventricular tachycardia 
or ventricular fibrillation occurring late after myocardial 
infarction is unknown. Studies (7,13,23) reporting a poor 
prognosis are based on relatively small 
who were treated with drugs, thereby 
history of the disease to an unnatural history. The present 
study is no exception with respect to the problem of describ- 
ing the natural history of the disease because all patients 
SAW Vol. 16. No. 3 
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ciinical course of patients 
menr in The Netherlands 
rather than on treat 
tomatic patients were ~CIL 
dependent ou the performance of an investigation. In pa- 
tients with ventric fibrillation or fast (>25@ beats/slain) 
ventricular tachyca a during antiarrhythmic drug treat- 
ment, proarrhytbmic effects 
cording to the ~e~a~t~o~ of 
Morganroth (16) in 1987, however, 
likelihood of the arrhythmia being induced by an a~t~arr~ytb~ 
mic drug was small (only 9 of 26 patients were receiving the 
drug for >30 days before t(i: arrhythmia occurred). To 
exclude proarrbytbm~c el-fects of s completely. how- 
ever, is impossible, but the maxi number of patients 
atients developing malignant omatic 
ventricular tachyarrhythmias after infarction ca f value 
in understanding pathophysiologic mechanisms. In this re- 
spect, several findings are noteworthy and suggest that we 
indeed studied patient.. Gth electrical instability as the main 
problem and not patients with other underlying cardiac 
abnormalities (such as pump failure) causing secondary 
ventricular arrhythmias. First, only a relatively small group 
of patients (13%) had signs or sympto s of a poor clinical 
condition during the first 6 weeks after myocardial infarc- 
tion. Second, we observed a high rate (17%) of primary 
sustained vent- icular tachycardia oc ventricAar fibrillation 
during the first 48 h 13f acut myocardial infarction. Other 
investigators (24-26) report rates of I% to 10% in “aver- 
age” patients with infarction. We also found that patients 
with these primary sustained ventricu arrhythmias had a 
lower risk of sudden death than did se without. These 
results are in contrast to the observations of Schwartz et al. 
(27), who found both a high total mortality rate and a high 
incidence of sudden death in patients with acute anterior 
myocardial infarction and primary ventricular fibrillation. 
coronary care unit, 
t bundle branch block. 
were treated wit 
eventually received iilvasive 
(29% to 52%) were orted. These studies. ho 
volved relatively sm numbers of patients; the 
tality rates could therefore be at least in part due 
early (within 2 to 6 weeks) after infarction. In our study, we 
observed a 38% and 40% mortality rate after 1 and 2 years, 
respectively, in 162 patients developing the ventricular ar- 
rhythmia within 6 weeks of infarction, whereas the rate was 
14% and 23%, respectively, in patients who had these 
arrhythmias after 6 weeks. Graboys et al. (13) reported an 
annual mortality rate of II%, but the underlying heart 
disease was myocardial infarction in only 50%. 
Thus, diRerent study designs, inclusion criteria and defi- 
nitions of the tachyarrhythmia led to different study groups 
and contributed to differences in mortality rates. In additiou, 
application of new or improved forms of treatment (35,36) 
could have played a rok in the diRerent mok‘ta~ity rates. 
developing the arrhythmia after a longer perio 
nale of two separate analyses is based on the 
the pathologic substrate (the m 
statistically significan: difference in the mortality rate be- 
tween the two groups (Table I) illustrates the clinical reie- 
Vance of two separate analyses. 
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Five baseline characteristics were independently predic- 
tive of total mortality if the analysis was undertaken for 
patients developing their hrst arrhythmia within 6 weeks 
after infarction, Age >70 years (risk ratio 4.5) is the stron- 
gest predictor fdeath. Cardiac arrest during the index ard@- 
miawas the second most important determinarat (risk ratio I .7). 
fii,q characteristic was also identified as a risk factor by 
Bnrgada et al. (37). The third factor found to be predictive of 
death is a poor clinical condition (not during the arrhythmia) 
according to the Killip classification <6 weeks after acute 
myocardial infarction (risk ratio 3.5). Although this classifica- 
tion is determined by more than left ventricular function alone, 
patients in Killip class 111 or IV probably have poor residual left 
ventricular function, This is in accordance with the fact that 
poor letI ventricular function after myocardial infarction is 
considered an independent determinant of death (2.3,38). The 
last two determinants, anterior location of infarction (risk ratio 
2.2) and multiple infarctions (risk ratio 1.6). also seem to be 
important in patients with decreased left ventricular function. 
Both factors, however, had an additional predictive value over 
the Killip classification. It is not surprising that multiple previ- 
ous infarctions and anterior infarction are determinants of 
death because both are associated with increased myocardial 
damage (39, 
In patients developing the arrhythmia >6 weeks after 
infarction, cardiac arrest, poor clinical condition during the 
first 6 weeks after infarction and multiple previous infarc- 
tions were also independent determinants of death. In addi- 
tion, Q wave infarction also emerged as a risk factor. This is 
remarkable because patients with non-Q -wave infarction are 
considered to have a similar or even higher incidence of 
postinfarction angina (40). recurrent infarction (41-43) and 
sudden death (40) in comparison with patients with Q wave 
infarction. In general, it seems that death in patients with 
sustained (symptomatic) ventricular tachyarrhythmias after 
myocardial infarction and that in the “average” patient with 
infarction is determined by the same variables, especially old 
age and poor left ventricular function. 
Multivariate analysis not only allows identification of 
determinants of total mortality, but quantification of risk 
given a particular risk profile. Most patients (62%) were 
grouped as being at low risk; the observed risk of death was 
12%. Ninety-two patients (24%) identified as being at inter- 
mediate risk showed an observed risk of 28%. whereas 55 
high risk patients (14%) had an observed risk of 54%. The 
risk profile described in Table 5 applies to patients with 
symptomatic ventricular tachycardia or ventricular fibrilla- 
tion after infarction, provided that a similar therapeutic 
strategy is followed. When the predictive function was 
derived, we included all patients (and subsequently all 
deaths) irrespective of the treatments given. Therefore, the 
predictive function applies prospectively from the moment 
of ventricular arrhythmia onward. Exclusions based on 
subsequent clinical decisions (such as performing surgc_ry or
other invasive therapies) would have hampered the ap 
bility of the risk function. 
No satisfactory model could he deth 
t!~ytktnic cvettts. Apparently, more speci 
(for example, those derived from angiographic and eiectro- 
physiologic studies) must be used to predict new arrhythmic 
events. In this study, however, details of these investiga- 
tions were not available in most patients at the time of the 
occurrence of the index arrhythmia. Using results of inves- 
the study would lead to an 
ients. oreover, the possible 
ment the results of these 
investigations cannot be established. Hence, in the present 
analysis, these results re not taken into account. 
. We only enrolled patients who 
were symptomatic during the arrhythmia. Thus, all results 
apply only to patients with at least one of the symptoms 
during the arrhythmia, as previously defined. In addition, 
patients were not registered if the attending physician 
thought the ventricular arrhythmia attributable to ischemia 
or pump failure. However, totally excluding ischemia or 
pump failure as the trigger initiating the arrhythmia is 
impossible. Finally, we cannot exclude patient selection due 
to referral, although we can show that the referral status of 
y did not influence their prognosis. 
iiieations. We assessed the 
clinical course of pa!ients with symptomatic ventricular 
tachycardia or ventricular fibrillation late after myocardial 
infarction who were given standard antiarrby!hmic treat- 
ment. At the time of the occurrence of the arrhythmia, the 
risk of total mortality within 1 year can be estimated from 
seven simpie and generally available clinical and ECG 
characteristics. In this way, patients can be identified as 
being at high, intermediate and low risk. This information 
can be helpful in establishing the optimal diagnostic and 
treatment strategy in the individual patient. If predicted risk 
is high. invasive diagnostic procedures (for example, elec- 
trophysiologic studies) and therapeutic interventions may be 
considered at an earlier stage. In addition. invasive therapy 
may become acceptable for high risk patients who otherwise 
would not have seemed to be good candidates for such 
treatment. Conversely, if predicted risk is low, a conserva- 
tive attitude seems justified and therapy should probably 
remain restricted to drug treatment of symptomatic epi- 
sodes. 
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